Natus Medical (BABY) Cut to “Hold” at Zacks Investment Research

Natus Medical (NASDAQ:BABY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

Separately, BidaskClub lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $46.50.

Shares of Natus Medical (BABY) traded down $0.25 during trading on Tuesday, hitting $38.30. 132,308 shares of the company traded hands, compared to its average volume of 382,073. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. The company has a market cap of $1,200.00, a price-to-earnings ratio of -638.33 and a beta of 0.84. Natus Medical has a 52 week low of $31.65 and a 52 week high of $43.60.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The company had revenue of $122.60 million during the quarter, compared to analyst estimates of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. Natus Medical’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period last year, the business earned $0.39 EPS. equities analysts anticipate that Natus Medical will post 1.74 EPS for the current fiscal year.

In related news, VP Dong Chune Christopher Chung sold 12,642 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the transaction, the vice president now owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William M. Moore sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of BABY. Dana Investment Advisors Inc. raised its position in shares of Natus Medical by 18.4% during the third quarter. Dana Investment Advisors Inc. now owns 66,903 shares of the medical equipment provider’s stock valued at $2,509,000 after buying an additional 10,409 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Natus Medical by 11.5% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 14,044 shares of the medical equipment provider’s stock valued at $527,000 after buying an additional 1,452 shares during the last quarter. Lyon Street Capital LLC raised its position in shares of Natus Medical by 26.9% during the third quarter. Lyon Street Capital LLC now owns 292,897 shares of the medical equipment provider’s stock valued at $10,984,000 after buying an additional 62,107 shares during the last quarter. Stifel Financial Corp raised its position in shares of Natus Medical by 8.1% during the third quarter. Stifel Financial Corp now owns 315,096 shares of the medical equipment provider’s stock valued at $11,870,000 after buying an additional 23,598 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Natus Medical by 3.3% during the third quarter. Dimensional Fund Advisors LP now owns 1,604,876 shares of the medical equipment provider’s stock valued at $60,183,000 after buying an additional 51,938 shares during the last quarter. 94.39% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/26/natus-medical-baby-cut-to-hold-at-zacks-investment-research.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit